Canine degenerative myelopathy (DM) is a progressive and debilitating neurological disease that primarily affects older dogs, leading to a gradual loss of function in the hind limbs. While initially recognized in German Shepherd Dogs, it has since been identified in numerous other breeds, presenting a significant challenge for veterinarians and dog owners alike. Understanding the causes, progression, and management of DM is crucial for providing the best possible care for affected animals. This article delves into the current knowledge surrounding DM, drawing from extensive veterinary research to shed light on this complex condition.
Understanding Degenerative Myelopathy
Degenerative myelopathy is a neurodegenerative disease characterized by the gradual degeneration of the white matter in the spinal cord, specifically affecting the myelin sheath and axons. This damage primarily begins in the thoracolumbar region of the spinal cord and progressively spreads. The onset of clinical signs typically occurs in dogs between 5 and 7 years of age, although this can vary.
Genetic Predisposition and Risk Factors
Research has identified a significant genetic component to DM. A specific mutation in the superoxide dismutase 1 (SOD1) gene has been strongly associated with the development of DM across various breeds. While the presence of this mutation, particularly homozygosity for the SOD1:c.118A allele, significantly increases a dog’s risk of developing DM, it does not guarantee the disease will manifest. Studies indicate that other genetic factors, such as variants within the SP110 nuclear body protein, may act as modifiers, influencing disease risk and age of onset.
Breeds with a higher reported prevalence of DM include:
- German Shepherd Dog
- Pembroke Welsh Corgi
- Boxer
- Rhodesian Ridgeback
- Chesapeake Bay Retriever
- Bernese Mountain Dog
- Kuvasz
- Hovawart
- Cavalier King Charles Spaniel
Clinical Signs and Progression
The hallmark of DM is a progressive, symmetrical, and painless weakness and ataxia (incoordination) in the hind limbs. Early signs often manifest as a subtle wobble or difficulty rising, which can be mistaken for other orthopedic conditions such as hip dysplasia or intervertebral disc disease. As the disease progresses, the hind limb weakness becomes more pronounced, leading to difficulties with ambulation, knuckling of the paws, and eventually paraparesis (weakness of both hind limbs) or paraplegia (inability to use the hind limbs).
In later stages, the neurological deficits can ascend to affect the thoracic limbs, and some dogs may develop lower motor neuron signs. Urinary and fecal incontinence can also occur, as well as respiratory disorders in the advanced stages, which can be a cause of death.
Diagnosis of Degenerative Myelopathy
Diagnosing DM antemortem (before death) can be challenging as there is no single definitive test. The diagnosis is often presumptive, based on a combination of clinical signs, breed predisposition, and the exclusion of other potential causes of hind limb weakness.
Diagnostic Tools and Techniques
- Genetic Testing: Testing for the SOD1 mutation is a crucial component of the diagnostic process. While a positive result, especially homozygosity, strongly suggests an increased risk, it is not diagnostic on its own as not all dogs with the mutation develop DM.
- Neurological Examination: A thorough neurological examination is essential to assess the extent and pattern of neurological deficits.
- Spinal Imaging: Magnetic Resonance Imaging (MRI) and myelography can be used to rule out other spinal cord diseases such as intervertebral disc disease, spinal tumors, or compressive lesions. However, DM itself does not typically show up on these imaging modalities unless there are secondary changes.
- Cerebrospinal Fluid (CSF) Analysis: While not diagnostic for DM, CSF analysis can help rule out inflammatory or infectious conditions. Recent research has identified phosphorylated neurofilament heavy (pNF-H) concentration in CSF as a promising biomarker for DM, showing increased levels in affected dogs and high sensitivity and specificity.
- Motor Unit Number Estimation (MUNE): This electrophysiologic technique can help quantify the lower motor neuron system and may be useful for monitoring disease progression, especially given the homology between canine DM and human ALS.
Management and Treatment of Degenerative Myelopathy
Currently, there is no cure for canine degenerative myelopathy. However, a multi-faceted approach focusing on slowing disease progression, managing symptoms, and maintaining the dog’s quality of life is recommended.
Therapeutic Strategies
- Physical Rehabilitation and Exercise: Regular, controlled exercise and physiotherapy are considered cornerstones of DM management. This can include walking, swimming, and specific rehabilitation exercises aimed at maintaining muscle mass, strength, and coordination. Studies have shown that intensive physiotherapy can significantly increase survival time and help dogs remain ambulatory longer.
- Nutritional Support and Supplements: While specific dietary recommendations for DM are still evolving, maintaining good overall nutrition is vital. Some research suggests that certain supplements, such as vitamins B, C, and E, and potentially curcumin, may offer neuroprotective benefits and help slow disease progression. Curcumin, in particular, has shown promise in preclinical studies for its antioxidant and anti-inflammatory effects and its ability to potentially inhibit the aggregation of mutant SOD1 proteins.
- Pharmacological Interventions: Medications such as ɛ-aminocaproic acid and N-acetylcysteine have been explored, though their efficacy is debated, with some studies suggesting they may not be an attractive alternative to conservative management. Gabapentin is often used to manage chronic pain associated with conditions like DM, and studies indicate it is generally well-tolerated and can be dosed to effect.
- Supportive Care: Addressing secondary issues like urinary incontinence through management strategies and providing assistive devices such as harnesses or wheelchairs can significantly improve a dog’s mobility and comfort.
Prognosis and Outlook
The prognosis for dogs diagnosed with degenerative myelopathy is generally poor, as it is a progressive and irreversible disease. However, with early intervention and consistent management, particularly through physical rehabilitation and supportive care, the progression of the disease can often be slowed, and the dog’s quality of life can be maintained for a significant period. The decision for euthanasia is typically based on the dog’s quality of life, degree of mobility, and the development of severe incontinence or respiratory distress.
The ongoing research into the genetic and molecular underpinnings of DM continues to offer hope for better diagnostic tools and potentially more effective therapeutic strategies in the future.